Most Recent Articles by Leslie Burgess, MA
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
Patients with relapsed or refractory MCL treated with ibrutinib had longer PFS with less toxicity than patients treated with temsirolimus in a phase 3 trial.
A new study provided firm evidence for the benefit of S-1 in treatment of patients with metastatic breast cancer (mBC).
Researchers have identified 55 genetic driver events involved in the development and progression of CLL, including 2 not previously known to be involved in human cancer development.
Patients receiving systemic therapy for metastatic non-small cell lung cancer (mNSCLC) outside of clinical trials are hospitalized significantly more often.
More Articles by Leslie Burgess, MA
Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of NeurotoxicityAug 25,2015
Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk DiseaseSep 17,2014
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- In Focus: Atezolizumab for Non-small Cell Lung Cancer
- FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments
- ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer
- Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity
- Bladder Cancer: Immunotherapies, Combination Therapies, and Current Research